Literature DB >> 18474382

Retigabine reduces the excitability of unmyelinated peripheral human axons.

P M Lang1, J Fleckenstein, G M Passmore, D A Brown, P Grafe.   

Abstract

Enhancement of membrane K(+) conductance may reduce the abnormal excitability of primary afferent nociceptive neurons in neuropathic pain. It has been shown that retigabine, a novel anticonvulsant, activates Kv7 (KCNQ/M) channels in the axonal/nodal membrane of peripheral myelinated axons. In this study, we have tested the effects of retigabine on excitability parameters of C-type nerve fibers in isolated fascicles of human sural nerve. Application of retigabine (3-10 microM) produced an increase in membrane threshold. This effect was pronounced in depolarized axons and small in hyperpolarized axons. This finding indicates that retigabine produces a membrane hyperpolarization which is limited by the K(+) equilibrium potential. The retigabine-induced reduction in excitability was accompanied by modifications of the post-spike recovery cycle. Most notable is the development of a late subexcitability at 250-400 ms following a short burst of action potentials. All effects of retigabine were blocked in the presence of XE991 (10 microM). The data show that Kv7 channels are present on axons of unmyelinated, including nociceptive, peripheral human nerve fibers. It is likely that activation of these channels by retigabine may reduce the ectopic generation of action potentials in neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18474382     DOI: 10.1016/j.neuropharm.2008.04.006

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  35 in total

1.  Some new insights into the molecular mechanisms of pain perception.

Authors:  David A Brown; Gayle M Passmore
Journal:  J Clin Invest       Date:  2010-04-26       Impact factor: 14.808

2.  Kv7.2 regulates the function of peripheral sensory neurons.

Authors:  Chih H King; Eric Lancaster; Daniela Salomon; Elior Peles; Steven S Scherer
Journal:  J Comp Neurol       Date:  2014-04-12       Impact factor: 3.215

3.  Cutaneous Aβ-Non-nociceptive, but Not C-Nociceptive, Dorsal Root Ganglion Neurons Exhibit Spontaneous Activity in the Streptozotocin Rat Model of Painful Diabetic Neuropathy in vivo.

Authors:  Laiche Djouhri; Asad Zeidan; Seham A Abd El-Aleem; Trevor Smith
Journal:  Front Neurosci       Date:  2020-05-25       Impact factor: 4.677

Review 4.  Understanding inflammatory pain: ion channels contributing to acute and chronic nociception.

Authors:  John E Linley; Kirstin Rose; Lezanne Ooi; Nikita Gamper
Journal:  Pflugers Arch       Date:  2010-02-17       Impact factor: 3.657

5.  Activation of KCNQ Channels Suppresses Spontaneous Activity in Dorsal Root Ganglion Neurons and Reduces Chronic Pain after Spinal Cord Injury.

Authors:  Zizhen Wu; Lin Li; Fuhua Xie; Junhui Du; Yan Zuo; Jeffrey A Frost; Susan M Carlton; Edgar T Walters; Qing Yang
Journal:  J Neurotrauma       Date:  2017-02-27       Impact factor: 5.269

Review 6.  Morphological and functional diversity of first-order somatosensory neurons.

Authors:  Eder Ricardo de Moraes; Christopher Kushmerick; Lígia Araujo Naves
Journal:  Biophys Rev       Date:  2017-09-09

Review 7.  Neural KCNQ (Kv7) channels.

Authors:  David A Brown; Gayle M Passmore
Journal:  Br J Pharmacol       Date:  2009-03-09       Impact factor: 8.739

8.  Cholinergic Modulation of Membrane Properties of Calyx Terminals in the Vestibular Periphery.

Authors:  Yugandhar Ramakrishna; Marco Manca; Elisabeth Glowatzki; Soroush G Sadeghi
Journal:  Neuroscience       Date:  2020-11-13       Impact factor: 3.590

Review 9.  Neuropathic pain: a maladaptive response of the nervous system to damage.

Authors:  Michael Costigan; Joachim Scholz; Clifford J Woolf
Journal:  Annu Rev Neurosci       Date:  2009       Impact factor: 12.449

10.  Enhancing m currents: a way out for neuropathic pain?

Authors:  Ivan Rivera-Arconada; Carolina Roza; Jose A Lopez-Garcia
Journal:  Front Mol Neurosci       Date:  2009-08-04       Impact factor: 5.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.